🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06922916
Starting soon Observational

Perioperative Risk Factors Related to the Prognosis of Lung Transplantation: A Retrospective Study

NCT06922916 · tracked via the Priya Life Science China tracker
Sponsor
Zhejiang University
Phase
Observational
Started
2025-04-22
Last updated
2025-04-22

Condition(s) studied

COPDInterstitial PneumoniaBronchiectasisRespiratory FailureIdiopathic Pulmonary Fibrosis (IPF)SilicosisPulmonary TuberculosisPulmonary HypertensionPulmonary Heart Disease

Study summary

This study analyzes patients who underwent lung transplantation at the First Affiliated Hospital of Zhejiang University from 2017 to 2024, focusing on anesthesia's impact on post-op results. It gathers patient data from hospital and Mediston systems, with main focus on in-hospital complications and secondary focus on ICU stay, post-op hospitalization, mortality, and intubation time. The research aims to deepen understanding of anesthetic management's role in lung transplant outcomes and guide improvements in perioperative anesthesia protocols.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Age \>18 years at time of transplantation * Received single or bilateral lung transplantation Exclusion Criteria: * Re-transplantation * Multi-organ transplantation * Autotransplantation * Incomplete medical records: Recipients with \>20% missing essential data elements in any of these categories:Preoperative baseline characteristics; Intraoperative parameters;Postoperative outcome measures

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000 Hangzhou Zhejiang

More Zhejiang University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06922916 on ClinicalTrials.gov ↗ ← All trials in China